Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05132699 · ClinicalTrials.gov registry record · Phase 1
Enhancing Prolonged Exposure With Cannabidiol to Treat Posttraumatic Stress Disorder
A Phase 1 study, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT05132699 is a Phase 1 study that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 21 participants.
The verdict
NCT05132699, a Phase 1 study, has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
The primary goal of this pilot project is to demonstrate the safety and feasibility of using Cannabidiol (CBD) in combination with standard of care prolonged exposure (PE) psychotherapy to reduce PTSD symptoms.
Interventions
- DRUG Placebo
- DRUG Cannabidiol (CBD) oral solution
- BEHAVIORAL Massed Prolonged Exposure (mPE)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2022-04-04 |
| Est. Completion | 2023-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05132699
The ClinicalTrials.gov registry entry for NCT05132699 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05132699 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05132699 about?
NCT05132699 is a clinical study titled "Enhancing Prolonged Exposure With Cannabidiol to Treat Posttraumatic Stress Disorder". The primary goal of this pilot project is to demonstrate the safety and feasibility of using Cannabidiol (CBD) in combination with standard of care prolonged exposure (PE) psychotherapy to reduce PTSD symptoms.
What is the current status of trial NCT05132699?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2022-04-04. Estimated completion is 2023-06-30.
What interventions are being tested in trial NCT05132699?
The interventions under investigation include: Placebo (DRUG), Cannabidiol (CBD) oral solution (DRUG), Massed Prolonged Exposure (mPE) (BEHAVIORAL).
Who is sponsoring clinical trial NCT05132699?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.